Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Teniposide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD
Deal Size : Inapplicable
Deal Type : Inapplicable
Post-line Treatment with Teniposide for C-Myc-driven Extensive-stage Small Cell Lung Cancer
Details : Teniposide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2025
Lead Product(s) : Teniposide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD
Deal Size : Inapplicable
Deal Type : Inapplicable